- Q1 2024 Blueprint Medicines Corp Earnings Call TranscriptMay 02, 2024$107 (+12.80%)Earnings
- Q4 2023 Blueprint Medicines Corp Earnings Call TranscriptFeb 15, 2024$87.57 (+14.02%)Earnings
- Blueprint Medicines Corp at JPMorgan Healthcare Conference TranscriptJan 08, 2024
- Q3 2023 Blueprint Medicines Corp Earnings Call TranscriptOct 26, 2023$55.22 (+25.61%)Earnings
- Blueprint Medicines Corp at Morgan Stanley Global Healthcare Conference TranscriptSep 11, 2023
- Q2 2023 Blueprint Medicines Corp Earnings Call TranscriptAug 02, 2023$54.3 (-15.34%)Earnings
- Blueprint Medicines Corp at Goldman Sachs Healthcare Conference TranscriptJun 14, 2023
- Blueprint Medicines Corp To Discuss The FDA Approval of AYVAKIT in ISM Call TranscriptMay 22, 2023
- Q1 2023 Blueprint Medicines Corp Earnings Call TranscriptMay 04, 2023$58.41 (+12.59%)Earnings
- Blueprint Medicines Corp at Stifel Targeted Oncology Days (Virtual) TranscriptApr 25, 2023
- Blueprint Medicines Corp at Barclays Global Healthcare Conference TranscriptMar 15, 2023
- Blueprint Medicines Corp To Discuss The Registrational PIONEER Trial Data Of AYVAKIT In Indolent SM Call TranscriptFeb 27, 2023
- Q4 2022 Blueprint Medicines Corp Earnings Call TranscriptFeb 16, 2023$44.71 (+1.54%)Earnings
- Blueprint Medicines Corp at JPMorgan Healthcare Conference TranscriptJan 11, 2023
- Q3 2022 Blueprint Medicines Corp Earnings Call & Investor Day TranscriptNov 01, 2022$48.24 (-6.94%)Earnings
- Blueprint Medicines Corporate call TranscriptAug 17, 2022
- Q2 2022 Blueprint Medicines Corp Earnings Call TranscriptAug 02, 2022$56.29 (+11.25%)Earnings
- Blueprint Medicines Corp Collaborations with Sixth Street and Royalty Pharma - Corporate Call TranscriptJun 30, 2022
- Blueprint Medicines Corp at JMP Securities Life Sciences Conference (Virtual) TranscriptJun 16, 2022
- Blueprint Medicines Corp at Goldman Sachs Global Healthcare Conference TranscriptJun 16, 2022
- Q1 2022 Blueprint Medicines Corp Earnings Call TranscriptMay 03, 2022$62.82 (+5.19%)Earnings
- Blueprint Medicines Corp Call to Discuss Data Reported at AACR TranscriptApr 08, 2022
- Blueprint Medicines Corp at Cowen Health Care Conference (Virtual) TranscriptMar 08, 2022
- Q4 2021 Blueprint Medicines Corp Earnings Call TranscriptFeb 16, 2022$74.9 (-9.99%)Earnings
- Blueprint Medicines Corp to Expand Precision Therapy Leadership in Lung Cancer with Acquisition of Lengo Therapeutics Inc Call TranscriptNov 29, 2021
- Q3 2021 Blueprint Medicines Corp Earnings Call TranscriptOct 28, 2021$113.33 (+8.75%)Earnings
- Blueprint Medicines Corp at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 09, 2021
- Q2 2021 Blueprint Medicines Corp Earnings Call TranscriptJul 29, 2021$84.74 (+2.21%)Earnings
- Blueprint Medicines Corp Corporate Call to Discuss the FDA Approval of AYVAKIT in Advanced SM TranscriptJun 16, 2021
- Blueprint Medicines Corp at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 10, 2021
- Blueprint Medicines Corp Annual Shareholders Meeting TranscriptJun 02, 2021
- Q1 2021 Blueprint Medicines Corp Earnings Call TranscriptApr 29, 2021$98.87 (+1.66%)Earnings
- Blueprint Medicines Corp AACR Conference Call TranscriptApr 12, 2021
- Blueprint Medicines Corp at Barclays Global Healthcare Conference (Virtual) TranscriptMar 10, 2021
- Q4 2020 Blueprint Medicines Corp Earnings Call TranscriptFeb 17, 2021$100.25 (+7.56%)Earnings
- Q3 2020 Blueprint Medicines Corp Earnings Call TranscriptOct 29, 2020$106.84 (+2.11%)Earnings
- Blueprint Medicines Corp Advanced Systemic Mastocytosis Topline Data Call TranscriptSep 22, 2020
- Blueprint Medicines Corp at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 16, 2020
- Blueprint Medicines Corp to Discuss the FDA Approval of GAVRETO Conference Call TranscriptSep 08, 2020
- Q2 2020 Blueprint Medicines Corp Earnings Call TranscriptJul 30, 2020$73.89 (+0.19%)Earnings
- Blueprint Medicines Corp to Discuss the Global Collaboration with Roche to Develop and Commercialize Pralsetinib for Patients with RET-Altered Cancers Call TranscriptJul 14, 2020
- Blueprint Medicines Corp Annual Shareholders Meeting TranscriptJun 23, 2020
- Blueprint Medicines Corp at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 10, 2020
- Blueprint Medicines Corp ASCO20 Conference Call TranscriptMay 29, 2020
- Q1 2020 Blueprint Medicines Corp Earnings Call TranscriptMay 06, 2020$58.97 (-1.29%)Earnings
- Blueprint Medicines Corp VOYAGER Corporate Call TranscriptApr 28, 2020
- Blueprint Medicines Corp AAAAI Call TranscriptMar 16, 2020
- Q4 2019 Blueprint Medicines Corp Earnings Call TranscriptFeb 13, 2020$63.81 (-1.44%)Earnings
- Blueprint Medicines Corp AYVAKITâ„¢ FDA Approval Conference Call TranscriptJan 09, 2020
- Blueprint Medicines Corp to Host Investor Event and Webcast to Review Initial Data from the PIONEER Trial Presented at ASH TranscriptDec 09, 2019
- Blueprint Medicines Corp Research and Development Day with Q3 2019 Blueprint Medicines Corp Earnings Call TranscriptNov 05, 2019$70.5 (+5.04%)Earnings
- Blueprint Medicines Corp at Morgan Stanley Healthcare Conference TranscriptSep 10, 2019
- Q2 2019 Blueprint Medicines Corp Earnings Call TranscriptAug 01, 2019$93.82 (-6.32%)Earnings
- Blueprint Medicines Corp Presents Updated EXPLORER Trial Data for Avapritinib in Patients with Systemic Mastocytosis at 24th EHA Congress TranscriptJun 17, 2019
- Blueprint Medicines Corp at Goldman Sachs Global Healthcare Conference TranscriptJun 12, 2019
- Blueprint Medicines Corp ASCO 2019 Analyst and Investor Reception TranscriptJun 03, 2019
- Blueprint Medicines Corp at Bank of America Merrill Lynch Health Care Conference TranscriptMay 15, 2019
- Q1 2019 Blueprint Medicines Corp Earnings Call TranscriptMay 09, 2019$82.3 (+7.22%)Earnings
- Blueprint Medicines Corp at Cowen Health Care Conference TranscriptMar 12, 2019
- Q4 2018 Blueprint Medicines Corp Earnings Call TranscriptFeb 26, 2019$76.42 (-1.56%)Earnings
Blueprint Medicines Corp ASCO20 Conference Call Transcript
Ladies and gentlemen, thank you for standing by, and welcome to the Blueprint Medicines Conference Call. (Operator Instructions) I would now like to hand the conference over to your speaker today, Kristin Hodous of Blueprint Medicines. Please go ahead.
Thank you, operator. Good morning, everyone, and thank you for joining us today to review the updated clinical data for pralsetinib and RET fusion-positive lung and thyroid which we announced this morning as part of the American Society of Clinical Oncology 2020 Virtual Scientific Program. You can access the press release for the data as well slides that we'll be reviewing today by going to the Investors section of our website at www.blueprintmedicines.com.
With me today with prepared remarks are Jeff Albers, our Chief Executive Officer; Dr. Andy Boral, our Chief Medical Officer; and Christy Rossi, our Chief Commercial Officer.
Before we get started,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)